Boiron controversies
Controversies tied to this brand in public sources. A listing is not a finding of fault.
Back to profile3 entries
2011
California Oscillococcinum class action
Consumers alleged that Boiron falsely represented Oscillococcinum as capable of curing flu symptoms and challenged the claimed medicinal value of its listed ingredient. The dispute was settled, with Boiron denying wrongdoing and agreeing to specified disclosures and marketing changes.
Criticism over contact with an Italian blog provider
Boiron contacted the internet provider of a blog that published criticism of homeopathy and displayed images of Boiron products. The episode prompted a backlash focused on freedom of expression.
FDA petitions concerning Oscillococcinum
The Center for Inquiry and the Committee for Skeptical Inquiry raised concerns with the FDA about Oscillococcinum's labeling and advertising, including how its alleged active ingredient and regulatory status were presented.